Pharmaceuticals
News Releases
2026 March
Pharmaceuticals
Otsuka Submits Application in Japan for Iclusig® for First-Line Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Pharmaceuticals
Otsuka Unveils New Repinatrabit Open-Label Extension Data in Phenylketonuria (PKU) Signaling Efficacy in Adolescents at the 2026 American College of Medical Genetics and Genomics (ACMG) Meeting
Pharmaceuticals
Launch of Joint Sales of the QuickNavi™-Campylobacter Antigen Diagnostic Kit in Japan
Nutraceuticals
New and Improved Calorie Mate JELLYEnhanced Taste and Balanced Nutrition, Now Even More Accessible
Corporate
Otsuka Pharmaceutical Appointments of Board Members and Statutory Auditors (PDF: 148.8 KB)
Corporate
Otsuka Pharmaceutical Named Tokyo Sports Promotion Model Company (Sports Practice Category) Employee and Communities Health Initiatives Recognized
Nutraceuticals
New Release: SOYJOY Azuki & HojichaA Deep Japanese Flavor with Gentle Sweetness and a Roasted Aroma
Pharmaceuticals
Paradise Ultrasound Renal Denervation System for the Treatment of Resistant Hypertension,Now Covered by Insurance and Commercially Available in Japan
2026 February
Nutraceuticals
New Product Release: /zeroz - a self-conditioning food that supports the body's natural abilities and contains plant-derived kaempferol to help make more effective use of oxygen
Nutraceuticals
Otsuka to Sponsor TOKYO MARATHON 2026Supporting Runners from Around the World Under the Theme "Believe in People's Potential."
Pharmaceuticals
REXULTI ® Listed in the "Essential Medicines List for the Ultra-Acute Phase of Disasters" by the Japanese Association for Disaster Medicine
Pharmaceuticals
Opening Egypt's First ORONAMIN C DRINK FactoryMeeting Growing Demand and Contributing to Community Health
Pharmaceuticals
Otsuka Enters into Agreement with South Korea-based Sky Labs for Exclusive Commercialization Rights in Japan to the Automated Blood Pressure Monitor CART BP pro First-in-world ring‑type blood pressure monitor that has received regulatory approval and insurance reimbursement in South Korea
Nutraceuticals
Tianjin Otsuka Beverage Opens New POCARI SWEAT Factory New facility to serve as a "health awareness hub"
2026 January
Pharmaceuticals
Otsuka Announces FDA Acceptance and Priority Review of New Drug Application for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults
Nutraceuticals
Otsuka Pharmaceutical Begins Rollout of PET Bottles Made from 100% Recycled PET ResinAiming to Realize a Decarbonized and Circular Society
Pharmaceuticals
Otsuka and Towa Conclude Basic Agreement on the Succession and Manufacturing Outsourcing of Long Listed Products, Establishing a Collaborative Framework for Stable Supply
Pharmaceuticals
DawnzeraTM (donidalorsen) granted European Union marketing authorisation for the prevention of hereditary angioedema
Pharmaceuticals
Otsuka Pharmaceutical and Dr. Keisuke Kataoka of the National Cancer Center Japan and Keio University Receive the Minister of Education, Culture, Sports, Science and Technology Award for Development of Gene Panel Test for Hematological Malignancies
Corporate
Otsuka Pharmaceutical Expands On-Site Solar Power Facilities at Factory Premises Accelerating Carbon-Neutral Initiatives
Corporate
Otsuka Holdings Submits Commitment Letter to Obtain Science-Based Targets Validation for the Entire Otsuka Group
2025 December
Nutraceuticals
Otsuka Pharmaceutical Supports Anti-Doping Initiative"CLEAN SPORT NIPPON SELECT"
Pharmaceuticals
Otsuka Initiates Global Phase 3 Clinical Trial Evaluating Repinatrabit for the Treatment of Phenylketonuria (PKU)
Pharmaceuticals
Otsuka Launches Frailty Prevention Support VR as Newest Content in FACEDUO VR Program Portfolio - Enables earlier detection of frailty to support health maintenance and prevent or defer the need for nursing care -
2025 November
Pharmaceuticals
Otsuka Receives FDA Accelerated Approval for VOYXACT® (sibeprenlimab-szsi) for the Reduction of Proteinuria in Adults with Primary Immunoglobulin A Nephropathy (IgAN) at Risk for Disease Progression
Pharmaceuticals
Otsuka Pharmaceutical Submits New Drug Application to U.S. FDA for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults
Pharmaceuticals
Otsuka launches NEXLETOL® in Japan
Pharmaceuticals
Donidalorsen Receives Positive CHMP Opinion for the Prevention of Hereditary Angioedema Attacks
Pharmaceuticals
Sibeprenlimab Phase 3 Data Presented at American Society of Nephrology Kidney Week 2025 Showed Proteinuria Reduction through 12 Months for the Treatment of Immunoglobulin A Nephropathy (IgAN) Trial Interim Analysis Outcomes Published in New England Journal of Medicine
Pharmaceuticals
Otsuka Announces First Participants Enrolled in Phase 3 Clinical Trial Evaluating Investigational Compound Quabodepistat for Drug-resistant Pulmonary Tuberculosis
Pharmaceuticals
Otsuka Signs Joint Research Agreement in Japan with National Cerebral and Cardiovascular Center -Purpose Is to Evaluate Salt Reduction Behavior Change in Heart Disease Patients Using a Nutritional Monitoring App-
2025 October
Pharmaceuticals
Otsuka Enters into Licensing Agreement for Ophthalmic Gene Therapy Drug Candidate 4D-150 (Anti-VEGF agent) ‐ Acquires Exclusive Development and Commercialization Rights for Asia-Oceania Region, Including Japan, from 4DMT ‐
Pharmaceuticals
Research on Work Productivity Among Japanese Workers Published in the Journal of Occupational Health — Visualizing the Impact of a Range of Diseases on Productivity Using Large-Scale Data —
2025 September
Pharmaceuticals
Otsuka and Lundbeck Receive Complete Response Letter from U.S. FDA for sNDA of REXULTI® (brexpiprazole) in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder (PTSD)
Pharmaceuticals
Otsuka Receives Approval in Japan for NEXLETOL®as a Treatment for Hypercholesterolemia
Nutraceuticals
POCARI SWEAT × TOKUSHIMA VORTIS Football Dream Project Phase 5 Welcomes Junior Soccer Players from the Middle East to Tokushima for International Exchange
Nutraceuticals
Joint Research on Athletes' Heat Acclimatization and Fluid/Nutrition Strategies at the World Athletics Championships Tokyo 25Provide New Insights for People Involved in Sports Around the World
Nutraceuticals
Otsuka Pharmaceutical Supports World Athletics Championships Tokyo 25 with POCARI SWEAT "Believe In Your Potential." is the Key Message We are Spreading to People Around the World
Pharmaceuticals
Otsuka Pharmaceutical Diagnostic Division Opens a New Laboratory in Tokyoto Advance Development of Next-Generation Medical Devices
2025 July
Corporate
Free Outdoor Live Music Event "EXCITING SUMMER in WAJIKI 2025" Live Stage Will Run on Solar Power Promoting More Sustainable Event Experience
Pharmaceuticals
Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on REXULTI® (brexpiprazole) in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder (PTSD)
Pharmaceuticals
Otsuka Acquires Worldwide Rights to Cantargia's CAN10 for Development and Commercialization as a Potential Treatment for Autoimmune Diseases
Nutraceuticals
Otsuka Pharmaceutical Launches Sales of POCARI SWEAT in India Expanding the Nutraceutical Business Globally
Pharmaceuticals
eMind, Tohoku University, and Otsuka Pharmaceutical Launch Epilepsy Smart Medical Joint Research Project (Phase II) Aiming to Start and Expand Epilepsy Treatment Support System
Pharmaceuticals
Otsuka Launches Comprehensive Support Program for Families of People with Severe Social Withdrawal (Hikikomori) in Collaboration with Hokkaido University
2025 June
Nutraceuticals
Otsuka Pharmaceutical Launches Portal for Corporate Health Services Empowering Employee Health Through Several Service Options
Nutraceuticals
POCARI SWEAT ICE SLURRY Adopted as a New Heat Illness Prevention at Expo 2025 Osaka, Kansai, Japan, Supporting the Safe and Secure Operation of the Expo
Nutraceuticals
Otsuka Obtains Exclusive License from Harbour BioMed for HBM7020: A Novel BCMAxCD3 Bispecific T-Cell Engager
Pharmaceuticals
New smartphone app, Rejoyn®, launched in Great Britain as a treatment for those living with depressive disorder
Pharmaceuticals
Otsuka Sibeprenlimab Phase 3 Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for the Treatment of Immunoglobulin A Nephropathy (IgAN)
2025 May
Pharmaceuticals
Otsuka Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
Nutraceuticals
Pharmavite Established a New Facility in Ohio, US, Dedicated to The Manufacturing of Gummy SupplementsFacilitating the Research and Development of Gummy Products
Pharmaceuticals
Otsuka Signs Joint Research Agreement with Keio UniversityIndustry-academia collaboration for infrastructure development toward the social implementation of psychedelics in Japan
2025 April
2025 March
Pharmaceuticals
Otsuka Files Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
Corporate
Otsuka Pharmaceutical is Expanding "Local Production and Local Recycling" of PET Bottle Initiatives in Cooperation with Local CommunitiesAgreement Signed with the Saga Eastern Environmental Facilities Association for Horizontal Recycling of PET Bottle
Pharmaceuticals
Rxulti® (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older
Corporate
Otsuka Pharmaceutical Appointments of Board Members and Statutory Auditors (PDF: 62.5 KB)
Nutraceuticals
New Release: SOYJOY Black Sesame A Bold Sesame Experience with a Delightful Popping Texture and Roasted Aroma
Pharmaceuticals
HemeSight®, the First-in-Japan Comprehensive Genomic Profiling Assay for Hematological Malignancies, Is Now on Sale - Insurance coverage begins on March 1, 2025
2025 February
Nutraceuticals
Otsuka Sponsor TOKYO MARATHON 2025 Supporting the Conditioning of Runners Worldwide with the Global Brand POCARI SWEAT
Corporate
Otsuka Holdings Receives Award by the Commissioner of the Consumer Affairs Agency at FY2024 Award for Good Practices of Consumer
Nutraceuticals
Otsuka Pharmaceutical to Offer "Wellness Energy" at the Expo 2025 Osaka, Kansai, JapanIntroducing a New Vision for "Shaping the Health of the Future"
Corporate
Otsuka Pharmaceutical Finalizes an Agreement with Fukuroi City on the Horizontal Recycling of PET BottlesPartnering with Its Factory to Promote a "Local Production and Local Recycling" Initiative for PET Bottles
Corporate
Otsuka Group Selected for CDP Climate Change A List for a Third Consecutive Year
2025 January
Nutraceuticals
Otsuka Pharmaceutical Launches the "Conditioning Supporter Training Program"Encouraging the Practice of Self-Conditioning
Nutraceuticals
Otsuka Pharmaceutical Releases the Total Conditioning Handbook for Well-Being to Support Life Performance
Pharmaceuticals
MIREVO®, the first neuropsychological testing program in Japan to support dementia treatment, now available
Pharmaceuticals
Otsuka Announces FDA Plans to Host an Advisory Committee Meeting to Discuss the sNDA for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder (PTSD)
Pharmaceuticals
European Medicines Agency Commences Review of Donidalorsen in Hereditary Angioedema
2024 December
Pharmaceuticals
JAMA Psychiatry Publishes Results of Otsuka and Lundbeck's Phase 3 Trial of Brexpiprazole in Combination with Sertraline in Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults
Pharmaceuticals
Otsuka and Jolly Good initiate the sale of FACEDUO Dementia Care Support VR
Corporate
Otsuka Expanding Use of Environmentally Friendly, Reusable Temperature-Controlled Containers - Initiated use for shipment of some pharmaceutical products to Europe -
2024 November
Nutraceuticals
Otsuka Pharmaceutical Launches POCARI SWEAT Basketball Dream Project to Promote Sports and International Exchanges
Pharmaceuticals
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
Pharmaceuticals
Otsuka Obtains Exclusive Global Licensing Rights from Ionis to Ulefnersen, a Potential Treatment for Amyotrophic Lateral Sclerosis Caused by Mutations in the Fused in Sarcoma Gene (FUS-ALS)
Pharmaceuticals
Otsuka launches Lupkynis® in Japan
Pharmaceuticals
Otsuka Provides Update on Sibeprenlimab, an Investigational Monoclonal Antibody for the Treatment of IgA Nephropathy in Adults
2024 October
2024 September
Corporate
Otsuka Group Establishes Solar Power Generation Facility in Naka, Tokushima The New Facility Advances the Company's Carbon Neutrality Initiative
Pharmaceuticals
HemeSight®, the First-in-Japan Comprehensive Genomic Profiling Assay for Hematological Malignancies, Receives Its First Regulatory Approval - HemeSight® hematological malignancies gene panel test approved in Japan -
Corporate
Heartful Kawauchi ReceivedJapan Organization for Employment of the Elderly, Persons with Disabilities and Job Seekers President's Award
Nutraceuticals
Otsuka Pharmaceutical Advancing Women's Health Business Bonafide Health Launched "Thermella", a Plant-derived Supplement to Support Menopausal Women in the U.S.
Pharmaceuticals
Otsuka Obtains Additional Indication for Rexulti®in Japan as an Adjunctive Treatment for Agitation Associated with Dementia due to Alzheimer's Disease
Pharmaceuticals
Otsuka Receives Approval in Japan for Lupkynis® as a Treatment for Lupus Nephritis
Pharmaceuticals
Otsuka Pharmaceutical Completes Acquisition of Jnana Therapeutics Inc.
Pharmaceuticals
Otsuka to Participate in the Orange Innovation Project, Promoted by Japan's Ministry of Economy, Trade and Industry
Corporate
Otsuka Pharmaceutical Launches Corporate Health Support Program "fitbiz"Supporting Employees in Building and Maintaining Healthy Habits
Nutraceuticals
Otsuka Pharmaceutical signs global supporter agreement with World AthleticsSponsorship will cover the World Athletics Championships Tokyo 25POCARI SWEAT will support the event with the key message "Believe In Your Potential."
Pharmaceuticals
Otsuka and Jolly Good Launch FACEDUO Dementia Care Support VR
Nutraceuticals
New from the Skincare Brand sakuraé Introducing Sakuraé Clear Cycle Lotion for Translucent and Healthy Skin
Nutraceuticals
U.S. Originated Nutrition Tracking Service "Vivoo" Launches in Japan Providing Easy Access to Nutritional Data to Support Healthy Lifestyles
2024 August
Pharmaceuticals
Otsuka Precision Health and Click Therapeutics Announce Launch of Rejoyn™, the First-And-Only Prescription Digital Therapeutic Cleared by the FDA for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms ーRejoyn, a first-of-its-kind digital treatment designed to help with cognitive control of emotion, is now available in mobile app stores and can be unlocked with a prescription from a healthcare providerー
Corporate
Otsuka Pharmaceutical Joins Project to Promote Use of Sustainable Aviation Fuel in Air Cargo TransportationーOperated by Tokyo Metropolitan Government, Aiming for a Decarbonized Societyー
Pharmaceuticals
Otsuka and Lundbeck Present New REXULTI® (brexpiprazole) Post Hoc Efficacy Data Analyses for Agitation Associated with Dementia Due to Alzheimer's Disease at Alzheimer's Association International Conference (AAIC) 2024
Corporate
Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc. - Transaction Includes JNT-517, a Potential First-In-Class Oral Treatment for Phenylketonuria (PKU) - - Expands Specialty and Autoimmune Portfolios and Drug Discovery Technologies -
2024 July
2024 June
Pharmaceuticals
Otsuka and Lundbeck announce FDA acceptance of sNDA filing for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD)
Nutraceuticals
Introducing a New Calorie Mate Block Production LineDeveloping a Sustainable Factory that is Kind to the Environment and Employees
Pharmaceuticals
Otsuka Concludes Expanded Licensing Agreement for Donidalorsen in Hereditary Angioedema, Expanding its Development and Sales Area to Asia Pacific including Japan
Nutraceuticals
Korea Otsuka Pharmaceutical Launches Soy Bar "SOYJOY"Introducing a New Concept of Healthy Snacking
2024 May
Corporate
Otsuka Pharmaceutical and Taiho PharmaceuticalCommence Material Recycling of Waste PTP Used in Pharmaceutical Packaging
Nutraceuticals
InnerSignal Introduces a New Basic Skincare Line Launch of "Repair Lotion" and "Repair Milk" to Address Epidermal Imbalance
Pharmaceuticals
Otsuka and Lundbeck Present Results from Three Clinical Trials of Brexpiprazole in Combination with Sertraline for the Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults
Pharmaceuticals
Otsuka to Terminate Development of AVP-786
Pharmaceuticals
Novartis launches Entresto® Granular Tablets for Pediatric Use, a formulation dedicated for pediatric patients
Pharmaceuticals
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment of Hypercholesterolemia
Nutraceuticals
Carbonated Nutritional Drink "ORONAMIN C DRINK" Debuts in Egypt
2024 April
Pharmaceuticals
Otsuka and Lundbeck submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD
Pharmaceuticals
Otsuka Works with Verily to Launch Longitudinal Mental Health Registry to Advance Novel Research in Psychiatry in the U.S.
Pharmaceuticals
FACEDUO Emotion Recognition Training VR now available - Support for those with developmental conditions such as autism spectrum disorder (ASD), which makes it difficult to read emotions -
Pharmaceuticals
U.S. Food and Drug Administration (FDA) Clearance of Rejoyn® First Prescription Digital Therapeutic Authorized in the U.S. for the Adjunctive Treatment of Major Depressive Disorder (MDD) symptoms
2024 March
Pharmaceuticals
Submission of an Application for the First Hematological Malignancies Gene Panel Test in Japan
Pharmaceuticals
Abilify Maintena® 960mg (aripiprazole) approved in the EU as the first once-every-two-months long-acting injectable for the maintenance treatment of schizophrenia
Pharmaceuticals
Novartis receives approval in Japan for Entresto® Granular Tablets for Pediatric Use, a formulation dedicated for pediatric patients with chronic heart failure
Pharmaceuticals
Otsuka Pharmaceutical's subsidiaries in Indonesia awarded Exemplar Award by Ending Workplace Tuberculosis (EWTB) for Otsuka's efforts to eliminate tuberculosis
Pharmaceuticals
Otsuka Announces Interim Data from Phase 2b/c Trial Indicating New Investigational Compound May Shorten Tuberculosis Treatment
Pharmaceuticals
Otsuka and Lundbeck Presented New Data Analyses on the Efficacy of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer's Disease
Corporate
Otsuka Pharmaceutical Enters into Cooperation Agreement on Heat Illness Prevention with Environmental Restoration and Conservation Agency
Pharmaceuticals
Otsuka and Sumitomo Revise License Agreement - Otsuka holds exclusive rights to develop, manufacture, and commercialize ulotaront and SEP-380135 worldwide -
Corporate
Otsuka Pharmaceutical Appointments of Board Members and Statutory Auditors (PDF: 70.1 KB)
Nutraceuticals
New SOYJOY Fig & Raisin A Whole-Soy Nutrition Bar Enhanced with Flavorful Figs
2024 February
Pharmaceuticals
Otsuka Enters into Investment Contract with AN Venture Partners
Nutraceuticals
Otsuka Sponsors TOKYO MARATHON 2024 POCARI SWEAT Supports Runners Achieve Their Goals
Nutraceuticals
Launch of AR-Based Nutrition Education Game App, "Mogumogu Town"Collect "Mogumin" Food Characters and Build Your Town
Pharmaceuticals
Sibeprenlimab Received U.S. FDA Breakthrough Therapy Designation for the Treatment of Immunoglobulin A Nephropathy (IgAN)
Corporate
Otsuka Pharmaceutical Launches "Kenkokeiei Tsunagaru Support ONLINE"Broadening Support for Resolving Corporate Health Challenges
Pharmaceuticals
Otsuka Announces Phase 3 Topline Results of AVP-786 in the Treatment of Agitation Associated with Dementia due to Alzheimer's Disease
Pharmaceuticals
Novartis Obtains Approval for Additional Indication of Pediatric Chronic Heart Failure for Angiotensin Receptor Neprilysin Inhibitor (ARNI) Entresto® Tablet = Novartis and Otsuka to provide information to healthcare professionals on additional indication for Entresto =
Pharmaceuticals
Otsuka and Jolly Good to Start Delivery of FACEDUO Content for Family Support of People with Severe Social Withdrawal (Hikikomori) FACEDUO is a virtual reality program for social skills training support
Corporate